Chemotherapy, FDA, Labelling and Patient Care

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Chemotherapy

FDA

Labelling

Patient Care

STAT+: FDA alters warning label for Carvykti CAR-T, although link to secondary cancers is unclear

STAT

DECEMBER 22, 2023

The Food and Drug Administration issued a change to the warning label for Legend Biotech and Janssen’s myeloma CAR-T, Carvykti or cilta-cel, adding that some secondary blood cancers have occurred following treatment for multiple myeloma with the cell therapy.

Labelling

Labelling Chemotherapy FDA Patient Care

New data reinforce Keytruda’s dominance in first-line lung cancer

pharmaphorum

SEPTEMBER 25, 2020

Furthermore, the duration of response with the PD-1 checkpoint inhibitor was nearly five times longer at 29 months versus just over six months with frontline chemotherapy.

Chemotherapy

Chemotherapy Labelling Patient Care FDA

Pharmacy Technician Pulse

STAT+: FDA alters warning label for Carvykti CAR-T, although link to secondary cancers is unclear

New data reinforce Keytruda’s dominance in first-line lung cancer

Stay Connected